Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Debt to Equity (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Debt to Equity for 4 consecutive years, with $0.26 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 98.53% to $0.26 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.26 through Dec 2025, up 98.53% year-over-year, with the annual reading at $0.26 for FY2025, 98.53% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.26 at TScan Therapeutics, up from $0.23 in the prior quarter.
  • The five-year high for Debt to Equity was $0.38 in Q1 2023, with the low at $0.12 in Q2 2024.
  • Average Debt to Equity over 4 years is $0.21, with a median of $0.19 recorded in 2023.
  • Peak annual rise in Debt to Equity hit 98.53% in 2025, while the deepest fall reached 37.76% in 2025.
  • Over 4 years, Debt to Equity stood at $0.29 in 2022, then crashed by 32.39% to $0.2 in 2023, then tumbled by 33.17% to $0.13 in 2024, then soared by 98.53% to $0.26 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.26, $0.23, and $0.18 for Q4 2025, Q3 2025, and Q2 2025 respectively.